^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunomodulator

    Related drugs:
    1d
    Large-scale transcriptomic data mining using explainable XGBoost and SHAP reveals shared biomarkers and molecular mechanisms between type-2 diabetes and triple-negative breast cancer for drug repurposing. (PubMed, BioData Min)
    Finally, we recommended sKGs-guided two repurposable common candidate drugs (tepotinib and ursodiol) for both diseases by molecular docking, ADME/T analysis and MD simulation studies. Thus, the results of this study could provide useful insights for researchers and medical professionals for improving the diagnostic and therapeutic strategies for the treatment TNBC with T2D as comorbidity.
    Journal
    |
    S100A9 (S100 Calcium Binding Protein A9) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1)
    |
    Tepmetko (tepotinib)
    2d
    Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=47, Completed, Beijing Friendship Hospital | Not yet recruiting --> Completed | N=26 --> 47 | Trial completion date: Mar 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • Zadaxin (thymalfasin)
    2d
    CHILURSO: Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, University Hospital, Montpellier | Trial completion date: Aug 2028 --> Aug 2029 | Initiation date: Feb 2026 --> Dec 2026 | Trial primary completion date: Sep 2027 --> Sep 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    2d
    Liensinine induces autophagy and apoptosis in hepatocellular carcinoma via reactive oxygen species-mediated inhibition of the PI3K/AKT/mTOR pathway. (PubMed, Tissue Cell)
    Lien exerts anti-HCC effects by promoting autophagy and apoptosis through ROS-mediated inhibition of the PI3K/AKT/mTOR pathway.
    Journal
    |
    BECN1 (Beclin 1)
    |
    hydroxychloroquine
    3d
    MSB-DR004: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov)
    P3, N=300, Active, not recruiting, Mesoblast, Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jul 2028 | Trial primary completion date: Oct 2026 --> Jul 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    3d
    Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous (clinicaltrials.gov)
    P3, N=6, Completed, Centre Hospitalier Universitaire de Nice | Unknown status --> Completed
    Trial completion
    4d
    ALLERDOG SWEDE: Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice (clinicaltrials.gov)
    P4, N=40, Recruiting, Karolinska Institutet
    New P4 trial
    4d
    FILAXOS: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=489, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=700 --> 489
    Enrollment closed • Enrollment change
    4d
    Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients (clinicaltrials.gov)
    P3, N=308, Recruiting, Materia Medica Holding
    New P3 trial
    5d
    Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. (PubMed, Cancer Res)
    Therapeutic Tα-1 supplementation produced strong synergy with chemotherapy to control established tumors in mice with high miR146a-5p expression in a TLR7-dependent manner. These findings establish Tα-1 as a pivotal endogenous microRNA chaperone that unlocks a critical limiting step of DC licensing, empowering robust antitumor immunity after chemotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TLR7 (Toll Like Receptor 7)
    |
    Zadaxin (thymalfasin)
    5d
    IQUALYSEP: Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=144, Completed, Rennes University Hospital | Unknown status --> Completed | N=250 --> 144
    Trial completion • Enrollment change • HEOR
    |
    mitoxantrone • Tysabri (natalizumab)
    8d
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Completed, Orionis Biosciences Inc | Active, not recruiting --> Completed
    Trial completion
    |
    ORB-011